FORE Biotherapeutics vs SpliSense
FORE Biotherapeutics vs SpliSense, compared side by side on 21 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: FORE Biotherapeutics is on 56/100 and SpliSense on 50/100.
Where each one leads
FORE Biotherapeutics
- our overall score: 56/100 against 50/100
- agent readiness: 37/100 against 21/100
- domain rating: 35/100 against 10/100
- headcount: 56 against 16
- funding raised: $232M against $28.5M
- LinkedIn following: 4,584 against 804
SpliSense
- headcount growth: +12.3% against +8.2%
At a glance
| Measure | FORE Biotherapeutics | SpliSense |
|---|---|---|
| What it is | Precision oncology company developing cancer therapies guided by proprietary functional genomics. | Biotechnology company developing inhaled therapies for genetic diseases, focusing on Cystic Fibrosis. |
| Category | Healthcare, Drug Development, Genomics, Next Generation Sequencing | Healthcare, Lung, Treatment, Biotech |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | Hardware, Software |
| Founded | 2011 | 2017 |
| Headquarters | Philadelphia, United States | Rehovot, Israel |
| Status | Active | Active |
Size, funding and growth
| Measure | FORE Biotherapeutics | SpliSense |
|---|---|---|
| Employees | 56 | 16 |
| Headcount growthLast 12 months | +8.2% | +12.3% |
| Total funding | $232M | $28.5M |
| Latest round | Series D-2 Extension | Series B |
| Valuation | $75.0M | Not published |
| LinkedIn followers | 4,584 | 804 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | FORE Biotherapeutics | SpliSense |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 56/100 | 50/100 |
| Traction | 58/100 | 50/100 |
| Team | 70/100 | 30/100 |
| Search visibility | 38/100 | 27/100 |
| Quality | 55/100 | 58/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (37/100) | F (21/100) |
| Domain ratingLink authority, 0-100 | 35/100 | 10/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | FORE Biotherapeutics | SpliSense |
|---|---|---|
| Hosting | Not detected | Self Managed |
| CMS | WordPress | WordPress |
| Frameworks | Jquery | Jquery |
FORE Biotherapeutics vs SpliSense: common questions
Which is better, FORE Biotherapeutics or SpliSense?
On our 0-100 score FORE Biotherapeutics rates higher (56/100 against 50/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 21 data points above: read the rows that match what you are buying for.
How do FORE Biotherapeutics and SpliSense compare on the numbers?
FORE Biotherapeutics leads on our overall score (56/100 against 50/100), agent readiness (37/100 against 21/100), domain rating (35/100 against 10/100), headcount (56 against 16), funding raised ($232M against $28.5M), LinkedIn following (4,584 against 804). SpliSense leads on headcount growth (+12.3% against +8.2%).
Read the full FORE Biotherapeutics review and pricing or the SpliSense review and pricing. You can also browse other FORE Biotherapeutics alternatives we track.